Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Both EACTS and STS have taken measures against bullying, disrespect, and other harmful behavior. Others may follow suit.

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary ...

New techniques and devices made headway in tough treatment scenarios, and guidelines stressed the need for collaborative care ...

It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Headlining the year’s developments were studies of catheter ablation and concomitant use of LAAO in patients with AF.

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

PLATO investigators dismiss the paper as nothing new, but some clinicians say that, after 15 years, it’s hard not to have ...